Related Experiment Videos
New anticoagulant drugs.
1Hamilton Civic Hospitals Research Center and McMaster University, Hamilton, Ontario L8V 1C3, Canada. jweitz@thrombosis.hhscr.org
Journal of Thrombosis and Thrombolysis
|November 17, 2001
Summary
Arterial and venous thrombosis cause significant illness and death. This review covers thrombogenesis, new anticoagulant strategies, and clinical applications for preventing and treating these conditions.
Area of Science:
- Cardiovascular Medicine
- Hematology
Background:
- Arterial and venous thrombosis are leading causes of morbidity and mortality.
- Arterial thrombosis underlies myocardial infarction, stroke, and limb gangrene.
- Venous thrombosis results in pulmonary embolism and post-phlebitic syndrome.
Purpose of the Study:
- To review the mechanisms of arterial and venous thrombogenesis.
- To outline novel anticoagulant strategies.
- To provide clinical perspectives on emerging anticoagulant therapies.
Main Methods:
- Literature review of arterial and venous thrombogenesis.
- Analysis of current and novel anticoagulant mechanisms.
- Synthesis of clinical data and perspectives on anticoagulant use.
Main Results:
- Arterial thrombi are platelet-rich; venous thrombi are fibrin-rich.
- Arterial thrombosis strategies target platelet function, often with anticoagulants.
- Venous thrombosis treatment primarily relies on anticoagulants.
Conclusions:
- Understanding thrombogenesis is key to developing targeted therapies.
- New anticoagulant strategies offer improved treatment options.
- Clinical implementation of novel anticoagulants requires careful consideration.